Functional Medicine Approach to Fibromyalgia

Gluten Sensitivity, Dysbiosis & KBMO FIT Testing in Clinical Practice

Understanding Primary versus Secondary Fibromyalgia through the through the Lens of Gut Health, SIBO & Functional Medicine

Tracey Randell

Registered Nutritionist, DipBCNH, IFMCP, MBANT, CNHC





Clinical Differences: Primary versus Secondary Fibromyalgia

Primary Fibromyalgia Presentation

- Sleep architecture dysregulation and non-restorative sleep sleep patterns
- Trauma history (physical or psychological) frequently present
- Central nervous system overactivation and sensitisation
- Gradual improvement trajectory with multi-modal approaches

Secondary Fibromyalgia Presentation


- Gut inflammation and digestive symptomatology prominent
- Food antigens driving systemic inflammatory responses
- Dysbiosis patterns evident on comprehensive testing
- Dramatic response to dietary modification and gut healing protocols

The key clinical distinction lies in treatment response velocity. Secondary fibromyalgia responds dramatically to targeted dietary changes, whilst primary fibromyalgia demonstrates more gradual improvement requiring comprehensive central sensitisation protocols.

The Gut-Immune-Pain Axis

Peripheral Inflammation

Gut-derived inflammatory mediators and food antigens trigger systemic immune activation



Cytokine Production

Pro-inflammatory cytokines cross blood-brain barrier, sensitising central pain processing pathways

Secondary Fibromyalgia


This mechanism explains how gut-driven inflammation can manifest as fibromyalgia fibromyalgia symptomatology

Central Sensitisation

Amplified pain signalling throughout nervous system, creating widespread pain from peripheral inputs

Understanding this bidirectional communication illuminates why addressing gut inflammation can rapidly resolve widespread pain in secondary pain in secondary fibromyalgia presentations.

Patient Overview, Ms E, age 34 years old



Presenting History

Female adult presenting with chronic widespread pain since childhood, accompanied by accompanied by irritable bowel syndrome, persistent insomnia, significant brain fog, and fog, and progressive hair loss.

latrogenic Factors

Extensive history of antibiotic use throughout adolescence and adulthood, combined with combined with daily antacid consumption, created profound microbiome disruption and disruption and digestive impairment.

Lifestyle Stressors

Pattern of overtraining coupled with insufficient caloric intake generated significant hypothalamic-pituitary-adrenal axis stress and metabolic dysfunction, further compromising gut barrier integrity.



The Perfect Storm: Converging Risk Factors



Frequent Antibiotics

Repeated courses throughout development led to microbiome depletion, reduced diversity, and loss of beneficial commensal organisms



Daily Antacid Use

Chronic acid suppression impaired protein digestion, reduced mineral absorption, and created small intestinal bacterial overgrowth risk



Low Caloric Intake

Insufficient energy provision resulted in micronutrient deficiency, impaired gut barrier maintenance, and compromised immune function



Excess Training Load

Overtraining without adequate recovery increased intestinal permeability through through physiological stress and reduced splanchnic blood flow



Comprehensive Testing Strategy

01

SIBO Breath Testing

Three-hour hydrogen and methane breath test to test to assess small intestinal bacterial overgrowth overgrowth and identify fermentation patterns patterns

02

Comprehensive Stool Analysis

Full digestive function assessment including markers of inflammation, immune function, digestive capacity, and microbial balance

03

KBMO FIT Testing

Food inflammation test measuring antigen load load across 132 foods, plus intestinal permeability permeability markers and candida antibody assessment

This multi-layered approach enables identification of overlapping gut dysfunctions whilst avoiding the common pitfall of single-mechanism attribution in mechanism attribution in complex inflammatory cases.

Metaxplore GI Plus - Comprehensive Stool Test Findings

1

Low Secretory IgA of <149.56 (500-2000 ug/g)

Impaired mucosal immunity indicating compromised first-line defence against pathogens pathogens and reduced capacity to maintain oral tolerance to food antigens

4

Reduced Pancreatic Elastase of 179.64 (>200 ug/g)

Low elastase levels suggesting reduced digestive capacity, likely secondary to chronic antacid use impairing pancreatic enzyme activation and secretion

3

Depleted Butyrate Producers

Significant reduction in butyrate-producing bacteria elevating gut inflammation risk and inflammation risk and compromising colonocyte energy metabolism and barrier function barrier function

4

Mild Calprotectin Elevation of 81.27 (<50 ug/g)

Modest inflammatory marker elevation, likely attributable to NSAID use for pain pain management rather than inflammatory bowel disease

5

Microbial Diversity of 4.17 (+0.22)

Diminished ecosystem diversity indicating dysbiosis and reduced microbial resilience, resilience, compromising metabolic flexibility and immune regulation

6

Microbial Richness of 213.00 (+0.34)

Decreased species richness reflecting impoverished gut microbiome with limited limited functional capacity and vulnerability to pathogenic colonization

SIBO Test Findings, Ms E

Breath Test Results Interpretation

Testing revealed methane of 17ppm at 140 minutes and so and so meets diagnostic criteria for Intestinal Methanogen Methanogen Overgrowth IMO.

Hydrogen levels were 16ppm at baseline rising to 24ppm at 100 minutes not diagnostic for H2 SIBO.

Collectively CH4 and H2 met diagnostic criteria for SIBO at SIBO at >15ppm.


Summary Report of Hydrogen and Methane Breath Analysis with Carbon Dioxide Correction


Gas Analysed	Patient Result 0- 100 mins	Expected difference 0- 100 mins		
Increase in Hydrogen (H ₂)	13	< 20		
Increase in Methane (CH ₄)	11	< 12		
Increase in Combined H ₂ & CH ₄	24	< 15		

Analysis of data suggests:				
Results indicate small intestinal bacterial overgrowth				
Intestinal Methanogenic Overgrowth (IMO)				


Small Intestinal Bacterial Overgrowth (SIBO) Hydrogen and Methane Breath after Lactulose consumption

Number	Expected Location	Interval	ppm H ₂	ppm CH₄	Combined	% CO ₂	fCO ₂ ¹
1	Small Intestine	Baseline	16	11	27	3.4	1.6
2		20 min	13	5	18	3.4	1.6
3		40 min	19	12	31	3.2	1.7
4		60 min	11	4	15	3.0	1.8
5		80 min				0.0	1.7
6		100 min	24	15	39	3.2	1.7
7	Transition	120 min	31	13	44	3.0	1.8
8	Large Intestine	140 min	27	17	44	3.3	1.7
9		160 min				0.0	NaN
10		180 min	43	15	58	3.2	1.7





KBMO FIT Test Findings: The Game-Changer



Phase 1: Intestinal Barrier Healing

Remove Reactive Foods

Eliminate all identified food antigens based on FIT results, with particular focus on strict gluten avoidance and removal of moderate reactors

Support Mucosal Immunity

Implement targeted supplementation to restore secretory IgA function and strengthen mucosal immune defences at epithelial surfaces

Reduce Inflammatory Load

Deploy anti-inflammatory nutrients and botanicals to decrease systemic inflammatory burden and support and support tissue repair processes

Introduce Digestive Support

Restore digestive capacity through betaine HCl, digestive enzymes, and bile support to address hypochlorhydria hypochlorhydria and maldigestion





Immediate Patient Action

Upon receiving her FIT test results, the patient implemented complete complete gluten removal before the follow-up consultation, demonstrating remarkable self-efficacy and engagement with her with her health journey.

This autonomous action, driven by clear objective evidence, exemplifies the power of comprehensive testing to catalyse behavioural change. The patient's immediate response demonstrated understanding of the gutimmune-pain connection and commitment to addressing root causes rather than solely managing symptoms.

Her proactive approach set the foundation for the remarkable clinical clinical improvements that followed over subsequent weeks.

Phase 2: Targeted Antimicrobial Intervention

Primary Objectives

Implementation of antimicrobials and nutrients specifically targeting candida overgrowth and dysbiotic bacterial populations identified through comprehensive stool analysis.

Predictable Die-Off Response

Week three saw the onset of Herxheimer reactions as microbial cell wall components released endotoxins. These manifested as transient itching, fatigue intensification, and mild headaches.

Patient Support Strategies

Managed die-off symptoms through enhanced detoxification support, hydration, fibre, and reassurance that symptoms indicate therapeutic progress.



Clinical Outcomes at Four Months

75%

100%

80%

85%

Global Improvement

Overall symptom reduction across across all presenting complaints complaints

Sleep Restoration

Complete normalisation of sleep quality and architecture

Pain Reduction

Significant decrease in widespread widespread pain intensity and frequency

IBS Resolution

Marked improvement in bowel function and abdominal symptoms symptoms

90%

Cognitive Function


Near-complete resolution of brain brain fog and mental clarity restoration

70%

Energy & Hair

Substantial energy improvement improvement and visible hair regrowth

Three-Week Response: Rapid Clinical Improvement



Phase 3: Microbiota Restoration & Resilience



Spore-Based Probiotics

Introduce resilient Bacillus species to re-establish beneficial bacterial populations and competitive exclusion mechanisms



Saccharomyces Boulardii

Deploy beneficial yeast for ongoing antifungal support and immune modulation, particularly targeting residual candida



PHGG Prebiotic Support

Provide partially hydrolysed guar gum to selectively feed beneficial bacteria without exacerbating SIBO tendencies



Butyrate Supplementation

Supply direct butyrate to support colonocyte metabolism, enhance barrier function, and promote anti-inflammatory signalling



Dietary Diversification

Gradually reintroduce diverse plant foods to build long-term microbiome resilience and metabolic flexibility

Root Cause Hypotheses

Gut Dysfunction

- SIBO contributing to visceral hypersensitivity and pain amplification
- Increased intestinal permeability enabling immune activation activation
- Food sensitivities driving systemic inflammatory cascades
- Hypochlorhydria causing maldigestion and downstream dysbiosis dysbiosis



Immune Activation

- Chronic low-grade inflammation antigenic exposure
- Impaired SIgA compromising mucosal defence
- Cytokine production driving central sensitisation
- Loss of oral tolerance mechanisms

Pain Amplification

- Peripheral inflammation sensitising central pain pathways
- Viscero-somatic convergence amplifying widespread pain
- Neuroimmune interactions perpetuating pain cycles
- Gut-brain axis dysfunction maintaining sensitisation

Summary - Why FIT Testing Was Decisive





Identified True Inflammatory Trigger

Revealed gluten as the primary driver rather than focusing exclusively on exclusively on SIBO or dysbiosis



Explained Multi-System Symptoms

Connected widespread pain, neurological symptoms, and gut dysfunction through unified mechanism



Validated Patient Experience

Provided objective confirmation of subjective symptoms, empowering patient engagement and adherence



Prevented Treatment Misdirection

Avoided exclusive SIBO focus that would have missed the primary primary pathogenic mechanism

Thank you for listening!

Questions?

What aspects of this case would you like to explore further?

Clinical Reflections

How does this case challenge or confirm your current approach to fibromyalgia?

FIT Testing Experience

How do you currently apply FIT testing in your clinical practice? What barriers or successes have you encountered?

Tracey Randell

Registered Nutritionist, DipBCNH, IFMCP, MBANT, CNHC

info@ibsclinics.co.uk

